Paul G. Allen Frontiers Group [to 27 Jul 2019]
No new digest content identified.


BMGF – Gates Foundation [to 27 Jul 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 27 Jul 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 27 Jul 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 27 Jul 2019]
25 Jul 2019
CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine

Oslo, Norway, and Saint-Herblain, France, July 25, 2019—Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, and the Coalition for Epidemic Preparedness Innovations (CEPI) hereby announce a new partnering agreement. With support from the European Union’s (EU’s) Horizon 2020 programme, CEPI will provide Valneva up to US$23.4 million for vaccine manufacturing and late-stage clinical development of a single-dose, live-attenuated vaccine (VLA1553) against Chikungunya. In line with CEPI’s commitment to equitable access, the funding will underwrite a partnership effort to accelerate regulatory approval of Valneva’s single-dose Chikungunya vaccine for use in regions where outbreaks occur and support WHO prequalification to facilitate broader access in lower and middle income countries.
Valneva will also maintain a stockpile of the vaccine candidate and work to transfer the secondary manufacturing of the drug product to partners for lower and middle income countries—where outbreaks of Chikungunya have occurred—to improve access to the vaccine for at-risk populations…


Clinton Health Access Initiative, Inc. (CHAI) [to 27 Jul 2019]
No new digest content identified.


EDCTP [to 27 Jul 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 27 Jul 2019]
No new digest content identified.


European Medicines Agency [to 27 Jul 2019]
News and press releases

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP)
22-25 July 2019


European Vaccine Initiative [to 27 Jul 2019]
No new digest content identified.


FDA [to 27 Jul 2019]
No new digest content identified.


Fondation Merieux [to 27 Jul 2019]
No new digest content identified.


Gavi [to 27 Jul 2019]
Latest news
INFUSE 2019: Harnessing innovation to accelerate urban immunisation coverage
Three new ‘Pacesetters’ selected to boost access to vaccine and primary health services for developing country populations living in complex urban settings
Geneva, 26 July 2019 – A chatbot technology powered by artificial intelligence (AI), an analytics platform using crowd-sourced data and a new approach to transgender community engagement have all been chosen to be 2019’s INFUSE Pacesetters…


GHIT Fund [to 27 Jul 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.


Global Fund [to 27 Jul 2019]
Faces of the Fight
23 July 2019
The fight against HIV, TB and malaria has many faces. They span ages and geographies and gender. Their diversity shows us that these diseases don’t affect one “type” of person. We can all see ourselves in these champions – in their challenges, their hopes and their strength.


Hilleman Laboratories [to 27 Jul 2019]
No new digest content identified.


Human Vaccines Project [to 27 Jul 2019]
No new digest content identified.


IAVI [to 27 Jul 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Statements and Press Releases
ICMRA statement about confidence in biosimilar products (for healthcare professionals) (July 2019)

ICMRA statement about confidence in biosimilar products (for patients and the public) (July 2019)



No new digest content identified.


IFRC [to 27 Jul 2019]
Selected Press Releases, Announcements
Asia Pacific, Philippines
Philippines: Urgent action needed to halt deadly dengue outbreak
Manila/Kuala Lumpur/Geneva, 26 July 2019 – Urgent action is needed to contain a dengue outbreak in the Philippines as cases continue to soar and an unprecedented nationwide emergency alert is issued…an alarming dengue outbreak with more than 115,000 cases reported since the beginning of the year – 85 per cent more than during the same period in 2018. To date, dengue has already led to 491 deaths, 30 per cent of them children between the ages of 5 and 9.
26 July 2019


IVAC [to 27 Jul 2019]
No new digest content identified.


IVI [to 27 Jul 2019]
IVI News & Announcements
IVI, KSC hold donation ceremony for Raphas
July 25, 2019 – SEOUL, South Korea. IVI and the Korea Support Committee for IVI (KSC) jointly held a donation ceremony in honor of Raphas, which has renewed commitment to support IVI’s vaccine development and delivery for children in developing countries. The Korean biopharmaceutical company, an IVI donor since 2015, will conduct a ‘Giving Vaccine’ campaign to use a portion of its sales to increase contributions to IVI through KSC…


JEE Alliance [to 27 Jul 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 27 Jul 2019]
Selected News; Project Updates, Reports
Journal article
Hepatitis E should be considered a neglected tropical disease

Affordable drugs and new hepatitis C treatment method save lives
24 Jul 2019

Addressing mounting health needs in Venezuela
24 Jul 2019


NIH [to 27 Jul 2019]
July 23, 2019
PrEP use high but wanes after three months among young African women
— Innovative adherence strategies needed to support long-term usage, NIH-funded study suggests.

Most women use vaginal ring for HIV prevention in open-label study
July 23, 2019 — NIH-supported research explored tool to expand HIV prevention choices for women.

NIH awards contract for acute flaccid myelitis natural history study
July 23, 2019 — The rare but serious condition causes muscle weakness and paralysis.


PATH [to 27 Jul 2019]
July 16, 2019 by PATH
PATH’s research on differentiated care in the Democratic Republic of the Congo recognized at the 2019 International AIDS Conference on HIV Science
July 22, 2019 by PATH
Yesterday at the 2019 International AIDS Conference on HIV Science (IAS 2019), PATH was announced as a recipient of the International AIDS Society/Merck Sharpe & Dohme Prize for Operational and Implementation Research in Differentiated Service Delivery in recognition of outstanding research in differentiated service delivery.
PATH was awarded the prize for a study looking at the effectiveness of client-centered HIV treatment distribution models in retaining people living with HIV on treatment in the Democratic Republic of the Congo (DRC)…


Sabin Vaccine Institute [to 27 Jul 2019]
Thursday, July 25, 2019 Thursday, July 25, 2019
Sabin Vaccine Institute and The Aspen Institute Release Report Calling for Bold, New, and Coordinated Commitments to Making Universal Influenza Vaccines a Reality
Report by cross-disciplinary team of global experts highlights urgent need for a vaccine that can protect the world against influenza; provides bold, actionable recommendations
WASHINGTON, D.C. – A new report released today by the Sabin-Aspen Vaccine Science & Policy Group, a joint initiative of the Sabin Vaccine Institute and the Aspen Institute, calls for an urgent, coordinated effort to amplify and focus resources on the long-sought, but overdue achievement of a universal influenza vaccine (UIV). The report, titled “Accelerating the Development of a Universal Influenza Vaccine,” is the result of a 9-month effort from a cross-disciplinary group of 24 internationally recognized experts and innovators with experience in government, public health, industry, finance, philanthropy, and advocacy. With 300,000 to 650,000 people killed annually from influenza and millions of lives threatened by the emergence of a pandemic strain, influenza remains one of the world’s most serious infectious disease threats…


UNAIDS [to 27 Jul 2019]
Selected Press Releases/Reports/Statements
25 July 2019
Botswana puts young people at the centre of its AIDS response

25 July 2019
Empowering women living with HIV in Djibouti to live dignified lives


UNICEF [to 27 Jul 2019]
Selected Statements, Press Releases, Reports

Press release
Partnerships and innovation help UNICEF deliver results for children in 150 countries
In 2018, UNICEF reached nearly half the world’s children with vaccines; provided 13.3 million bed nets and nearly 50,000 tonnes of ready-to-use food
In 2018, UNICEF helped children by:
:: Procuring 2.36 billion doses of vaccines to fight a variety of diseases including measles, diphtheria, tetanus and HPV, and reach nearly half the world’s children
:: Providing children access to safe water with 1.26 billion water purification tablets and chlorination/flocculation sachets
:: Protecting children from mosquito-borne diseases using 13.3 million bed nets
:: Treating children suffering from malnutrition with 47,760 tonnes of ready-to-use therapeutic food
:: Helping children get back in the classroom with 4.5 million schoolbags and 84,000 education kits…


Vaccination Acceptance Research Network (VARN) [to 27 Jul 2019]
No new digest content identified.


Vaccine Confidence Project [to 27 Jul 2019]
Article of the week – Posted on 21 Jul, 2019
An excellent, thoughtful article on the urgent need to diffuse polarized debates to more civil, open dialogue with room for differences –  HL
Preserving Civility in Vaccine Policy Discourse: A Way Forward
Gregory A. Poland, MD; Jon C. Tilburt, MD; Edgar K. Marcuse, MD
Published in JAMA 16 July 2019


Vaccine Education Center – Children’s Hospital of Philadelphia [to 27 Jul 2019]
No new digest content identified.


Wellcome Trust [to 27 Jul 2019]
Opinion | 25 July 2019
Initiative brings biologists together to crack the secrets of human development
Andrew Chisholm and Sheny Chen
Cellular and Developmental Sciences team Wellcome
The Human Developmental Biology Initiative is a £10 million project to provide insights into how humans develop – from one cell to billions of different cells that make up our tissues and organs.


The Wistar Institute [to 27 Jul 2019]
No new digest content identified.


World Organisation for Animal Health (OIE) [to 27 Jul 2019]
No new digest content identified.





BIO [to 27 Jul 2019]
Jul 23 2019
Senate Finance Drug Pricing Proposal Misses the Mark
“While we’re pleased that the Senate Finance Committee proposal caps what beneficiaries have to pay out of pocket for medicines under Medicare Part D, it adopts a framework that punishes some of the most innovative biotech cures and transformative therapies.”


DCVMN – Developing Country Vaccine Manufacturers Network [to 27 Jul 2019]
No new digest content identified.


IFPMA [to 27 Jul 2019]
No new digest content identified.


PhRMA [to 27 Jul 2019]
July 25, 2019
PhRMA Statement Opposing Senate Finance Committee Drug Pricing Legislation
“…The Senate Finance Committee legislation is the wrong approach to lowering drug prices. It would siphon more than $150 billion from researching and developing new medicines and give those savings to the government, insurers and PBMs, instead of using those savings to lower costs for seniors at the pharmacy counter…”